Headache News and Research

Latest Headache News and Research

AstraZeneca announces Phase III study results of naloxegol in patients with non-cancer pain

AstraZeneca (NYSE: AZN) today announced the results of a Phase III long-term safety and tolerability study of the once-daily 25mg dose of naloxegol, in patients with non-cancer pain and opioid-induced constipation (OIC).

15 Oct 2013

FDA approves OTREXUP injection for adults with RA, children with active pJIA

Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

14 Oct 2013

Peripheral nerve stimulation reduces headache intensity by more than 70%

For the more than 45 million Americans who suffer from chronic headaches, relief may be on the way in the form of an electric pulse, according to a study presented at the ANESTHESIOLOGY 2013 annual meeting.

14 Oct 2013

FDA accepts, files Genentech's sBLA for subcutaneous use of Xolair in people with CIU

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted and filed the company's supplemental Biologics License Application for subcutaneous use of Xolair (omalizumab) in people with Chronic Idiopathic Urticaria who remained symptomatic despite treatment with H1-antihistamine therapy at approved doses.

11 Oct 2013

Crucial role of orthopedic surgeons in diagnosing mTBI among trauma care patients

In the United States, approximately 1.4 million people suffer a traumatic brain injury (TBI) each year. Of those injuries, three out of four are minor TBI (mTBI)-a head injury that causes a temporary change in mental status including confusion, an altered level of consciousness, or perceptual or behavioral impairments.

11 Oct 2013

Adempas drug gets FDA approval for treatment of pulmonary hypertension

The U.S. Food and Drug Administration today approved Adempas (riociguat) to treat adults with two forms of pulmonary hypertension. Pulmonary hypertension is caused by abnormally high blood pressure in the arteries of the lungs.

10 Oct 2013

Team Ritter to raise funds for John Ritter Foundation for Aortic Health at ING NYC Marathon

Friends and family members of people with thoracic aortic disease and fans of the late legendary comedic actor John Ritter will come together as Team Ritter to raise funds for the John Ritter Foundation for Aortic Health at the ING New York City Marathon on Nov. 3, 2013.

10 Oct 2013

Researchers find no serious adverse effects of HPV vaccine in girls

Researchers at Karolinska Institutet in Sweden and their Danish colleagues have monitored HPV-vaccinated girls via patient data registries in order to examine the incidence of a wide range of diseases and thus determine if there are any serious adverse effects of the vaccine. Their results show no significant increase of the examined diseases in the vaccinated girls relative to their unvaccinated peers.

10 Oct 2013

ARIAD announces changes in Iclusig product labeling to reflect updated safety information

ARIAD Pharmaceuticals, Inc. today announced results of its review of updated clinical data from the pivotal PACE trial of Iclusig® (ponatinib) and actions that it is taking following consultations with the U.S. Food and Drug Administration (FDA).

9 Oct 2013

FMCNA encourages dialysis patients to get vaccinated against flu

With early cases of seasonal flu already being reported in the U.S., Fresenius Medical Care North America (FMCNA), the nation's leading network of dialysis facilities, is strongly encouraging dialysis patients to get flu shots to protect themselves against this common infectious disease.

9 Oct 2013

Bayer HealthCare receives FDA approval for Adempas tablets

Bayer HealthCare announced today that the United States Food and Drug Administration has approved Adempas (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class; and (ii) the treatment of adults with pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity, improve WHO functional class and delay clinical worsening.

9 Oct 2013

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520, its RNAi-based candidate against chronic hepatitis B virus infection.

9 Oct 2013

Acorda Therapeutics initiates second clinical trial of Glial Growth Factor 2 in heart failure patients

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the first patient has been enrolled in the second clinical trial of Glial Growth Factor 2 (GGF2). This Phase 1b single-infusion trial in people with heart failure will assess tolerability of three dose levels of GGF2, and also includes several explorative measures of efficacy.

9 Oct 2013

Mobilized medical care is necessary to better serve Haitian population after earthquake

Three years after an earthquake killed more than 200,000 people and left an estimated 1.5 million people homeless in Haiti, a Henry Ford Hospital study found that more mobilized medical care is necessary to bridge cultural and health care barriers and better serve the Haitian population.

7 Oct 2013

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.

7 Oct 2013

Experts develop way to reduce radiation exposure in children who require repeated brain CT scans

A team of pediatric neurosurgeons and neuroradiologists at the Johns Hopkins Children's Center has developed a way to minimize dangerous radiation exposure in children with a condition that requires repeat CT scans of the brain.

4 Oct 2013

Data analyses from Brisdelle Phase 3 pivotal trials to be showcased at NAMS' meeting

Noven Pharmaceuticals, Inc., today announced that 11 presentations, featuring data analyses from its Phase 3 pivotal trials that supported the recent U.S. Food and Drug Administration approval of Brisdelle (paroxetine capsules, 7.5 mg/day) for the treatment of moderate to severe vasomotor symptoms associated with menopause, will be showcased at the 2013 Annual Meeting of The North American Menopause Society in Dallas on Oct. 9-10.

2 Oct 2013

First Edition: September 30, 2013

Today's headlines include reports about the readiness of the health law's online marketplaces and other key provisions the day before their Oct. 1 launch date even as the looming government shutdown becomes more of a reality.

30 Sep 2013

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis.

30 Sep 2013

Technical glitches delay online signups for small business and Spanish speakers

The Obama administration acknowledged glitches Thursday that will delay online enrollment for small businesses and Spanish-language speakers in the 34 states that elected to not set up their own insurance marketplaces. The postponements amount to a few weeks in the six-month open enrollment period and will not affect the Jan. 1 start date for coverage.

30 Sep 2013

Headache News and Research

Latest Headache News and Research

AstraZeneca announces Phase III study results of naloxegol in patients with non-cancer pain

FDA approves OTREXUP injection for adults with RA, children with active pJIA

Peripheral nerve stimulation reduces headache intensity by more than 70%

FDA accepts, files Genentech's sBLA for subcutaneous use of Xolair in people with CIU

Crucial role of orthopedic surgeons in diagnosing mTBI among trauma care patients

Adempas drug gets FDA approval for treatment of pulmonary hypertension

Team Ritter to raise funds for John Ritter Foundation for Aortic Health at ING NYC Marathon

Researchers find no serious adverse effects of HPV vaccine in girls

ARIAD announces changes in Iclusig product labeling to reflect updated safety information

FMCNA encourages dialysis patients to get vaccinated against flu

Bayer HealthCare receives FDA approval for Adempas tablets

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Acorda Therapeutics initiates second clinical trial of Glial Growth Factor 2 in heart failure patients

Mobilized medical care is necessary to better serve Haitian population after earthquake

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

Experts develop way to reduce radiation exposure in children who require repeated brain CT scans

Data analyses from Brisdelle Phase 3 pivotal trials to be showcased at NAMS' meeting

First Edition: September 30, 2013

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

Technical glitches delay online signups for small business and Spanish speakers

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Headache News and Research

Latest Headache News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in